Eli Lilly and Company· @EliLillyandCo · X·· 2026-08-03精选AI 评分58
AI 导读
礼来宣布，其一款在研疗法获得FDA授予的突破性疗法认定，用于既往接受过治疗的某种晚期胰腺癌患者。礼来表示该认定将有助于推进这一潜在治疗选择。原文未披露具体药物名称、胰腺癌亚型及临床数据。
推荐理由
礼来披露其一款在研疗法获FDA突破性疗法认定，用于既往接受过治疗的晚期胰腺癌患者。
正文
A Breakthrough Therapy designation granted by the @FDA will help advance a potential treatment option that could be meaningful for previously treated patients with a certain form of advanced #pancreaticcancer.
Learn more: https://go.lilly.com/xzz9bq
来源：Eli Lilly and Company · x.com